Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus

Clinical Laboratory

Volumn 60, Issue 12, 2014, Pages 1969-1976

  Kong, Dexiao ^a,b   Zhuang, Xianghua ^a   Wang, Daoqing ^a   Qu, Huiting ^a,b   Jiang, Yang ^a,b   Li, Xiaomei ^a   Wu, Wenxiu ^a,b   Xiao, Juan ^a,b   Liu, Xiaoli ^a,b   Liu, Junli ^a   Li, Ai ^a,b   Wang, Juandong ^a,b   Dou, Aixia ^a,b   Wang, Yongjing ^a,b   Sun, Junhua ^a   Lv, Hong ^a   Zhang, Guihua ^a   Zhang, Xuhua ^b   Chen, Shihong ^a   Ni, Yihong ^a   Zheng, Chengyun ^a,b,c   more..

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood glucose; Mesenchymal stem cells; Safety; T2DM; Therapeutic effects

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; C PEPTIDE; CD11B ANTIGEN; CD14 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; GLUCOSE; HEMOGLOBIN A1C; HLA DR ANTIGEN; INSULIN; ORAL ANTIDIABETIC AGENT; PLASMA PROTEIN; THY 1 ANTIGEN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY MASS; CD8+ T LYMPHOCYTE; CELL COUNT; CELL DIFFERENTIATION; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; DIET RESTRICTION; DOWN REGULATION; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION; PATIENT SAFETY; PHENOTYPE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TREATMENT RESPONSE; UMBILICAL CORD; BLOOD; CELL CULTURE; CHINA; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PILOT STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-PEPTIDE; CELLS, CULTURED; CHINA; CORD BLOOD STEM CELL TRANSPLANTATION; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PILOT PROJECTS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922058213     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2014.140305     Document Type: Article

References (34)

1. Ehlers M, Papewalis C, Stenzel W, et al. Immunoregulatoiy natural killer cells suppress autoimmunity by down-regulating antigen-specific CD8+ T cells in mice. Endocrinology 2012;153:4367-79.
2. Novak J, Novakova L. Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells. Clinical and Experimental Medicine 2013;13:229-37.
3. Wang RH, Kim HS, Xiao C, Xu X, Gavrilova O, Deng CX. Hepatic Sirtl deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. The Journal of Clinical Investigation 2011;121:4477-90.
4. Imam K. Clinical features, diagnostic criteria and pathogenesis of diabetes mellitus. Advances in Experimental Medicine and Biology 2012;771:340-55.
5. Dunmore SJ, Brown JE. The role of adipokines in beta-cell failure of type 2 diabetes. The Journal of Endocrinology 2013;216:T37-45.
6. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013;339:166-72.
7. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression. Transplantation 2010;90:1312-20.
8. Gieseke F, Bohringer J, Bussolari R, Dominici M, Handgretinger R, Muller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010;116:3770-9.
9. Noone C, Kihm A, English K, O'Dea S, Mahon BP. IFN-gamma Stimulated Human Umbilical-Tissue-Derived Cells Potently Suppress NK Activation and Resist NK-Mediated Cytotoxicity in vitro. Stem Cells and Development 2013;22:3003-14.
10. Sui W, Hou X, Che W, et al. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clinical immunology 2013;148:186-97.
11. Ball LM, Bernardo ME, Roelofs H, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. British Journal of Haematology 2013;163:501-9.
12. Oviedo A, Yanez R, Colmenero I, et al. Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia. Cell Transplantation 2013;22:1381-94.
13. Casiraghi F, Remuzzi G, Perico N. Mesenchymal stromal cells to promote kidney transplantation tolerance. Current Opinion in Organ transplantation 2014; Feb; 19(1):47-53.
14. Murphy MB, Moncivais K, Caplan Al. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental & Molecular Medicine 2013;45:e54.
15. Milanesi A, Lee JW, Li Z, et al. Beta-Cell regeneration mediated by human bone marrow mesenchymal stem cells. PloS One 2012;7:e42177.
16. Si Y, Zhao Y, Hao H, et al. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity. Diabetes 2012;61:1616-25.
17. Shrestha C, Zhao L, Chen K, He H, Mo Z. Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media. International Journal of Endocrinology 2013;2013:592454.
18. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. Journal of Immunology 2009;183:993-1004.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
20. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7.
21. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Research and Clinical Practice 1998;40 Suppl: S21-5.
22. Mazzola N. Review of current and emerging therapies in type 2 diabetes mellitus. The American Journal of Managed Care 2012;18:S17-26.
23. Velloso LA, Eizirik DL, Cnop M. Type 2 diabetes mellitus - an autoimmune disease? Nature Reviews Endocrinology 2013;9:750-5.
24. DeFuria J, Belkina AC, Jagannathan-Bogdan M, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proceedings of the National Academy of Sciences of the United States of America 2013;110:5133-8.
25. Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S. Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells 2007;25:2837-44.
26. Bell GI, Broughton HC, Levac KD, Allan DA, Xenocostas A, Hess DA. Transplanted human bone marrow progenitor subtypes stimulate endogenous islet regeneration and revascularization. Stem Cells and Development 2012;21:97-109.
27. Bell GI, Meschino MT, Hughes-Large JM, Broughton HC, Xenocostas A, Hess DA. Combinatorial human progenitor cell transplantation optimizes islet regeneration through secretion of paracrine factors. Stem Cells and Development 2012;21:1863-76.
28. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. Journal of Immunology 2008;181:3933-46.
29. Li X, Wang D, Liang J, Zhang H, Sun L. Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplantation 2013;48:544-50.
30. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
31. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering 2001;7:211-28.
32. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 2004;22:649-58.
33. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006;91:1017-26.
34. Spanou M, Tziomalos K. Bariatric surgery as a treatment option in patients with type 2 diabetes mellitus. World Journal of Diabetes 2013;4:14-8.